Lakefront Biotherapeutics Nine-Month Revenue Falls 88% as Gilead Rights End
Lakefront Biotherapeutics reported an 88% drop in revenue for the nine-month period as Gilead access rights ended.
Related stories
Corteva Posts Lower Third-Quarter Sales, Updates Full-Year Guidance
Corteva said challenges in Brazil’s crop protection market weighed on sales. It reported a pro forma loss of $56 million, or 8 cents a share, versus a year-earlier profit of $58 mi
M impact | EARNINGS | Nov 11, 2026, 10:30 PM UTC
Xero Raises FY27 Operating Revenue Forecast to NZD 3.77B–3.83B
Xero raised its FY27 operating revenue forecast to NZD 3.77 billion–3.83 billion.
M impact | EARNINGS | Nov 11, 2026, 10:30 PM UTC
CoreWeave results drive broad tech rally
US tech stocks surged Wednesday following stronger-than-expected CoreWeave earnings, as the AI trade recovered after last week’s selloff. Despite the company’s massive borrowing, i
H impact | EARNINGS | Nov 11, 2026, 10:20 PM UTC
Clairvest Reports C$27.8M Net Income in Q2
L impact | EARNINGS | Nov 11, 2026, 10:05 PM UTC
Ibovespa Closes Higher on Fiscal Adjusment Prospects
The Ibovespa rose 0.4% to close at 172,060 on Wednesday after markets received moderately positively the first signals about the fiscal package President Lula is preparing for 2027
H impact | EARNINGS | Nov 11, 2026, 09:59 PM UTC
Inghams Cuts FY27 EBITDA Guidance Range Top End by A$10 Million
M impact | EARNINGS | Nov 11, 2026, 09:53 PM UTC